(Q42657606)

4 November 2017

The effects of cholecystokinin A and B receptor antagonists on exploratory behaviour in the elevated zero-maze in rat. (English)

1 reference

4 November 2017

1 reference

Matto V

1

1 reference

PubMed ID

9175618

4 November 2017

Harro J

series ordinal

2

1 reference

PubMed ID

9175618

4 November 2017

Allikmets L

series ordinal

3

1 reference

4 November 2017

1 March 1997

1 reference

4 November 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Neuropharmacology

1 reference

4 November 2017

36

1 reference

4 November 2017

389-396

1 reference

4 November 2017

3

1 reference

Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety.

4 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Defense system psychopharmacology: an ethological approach to the pharmacology of fear and anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Anxiolytic effects of CCK-B antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Actions of buspirone in a putative model of anxiety in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

CCK8 effects on motivational and emotional states of rats involve CCKA receptors of the postero-median part of the nucleus accumbens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Psychopharmacology of anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

CCK in animal and human research on anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Neuropeptides in perspective: the last ten years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Effects of benzodiazepine receptor inverse agonists on locomotor activity and exploration in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)-A receptor gene knockout rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Ethologically-based animal models of anxiety disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

The relation between fear induced by novel stimulation and exploratory drive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Two brain cholecystokinin receptors: implications for behavioral actions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Atypical anxiolytic profile of buspirone and a related drug, SM-3997, in a modified forced swim test employing straw suspension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

The effects of drugs acting at GABA-benzodiazepine-barbiturate receptor complex on the behaviour of sleep-deprived mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Evidence for an involvement of the brain cholecystokinin B receptor in anxiety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

"Anxiolytic" and "anxiogenic" benzodiazepines and beta-carbolines: effects on aggressive and social behavior in rats and squirrel monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0028-3908%2897%2900011-7

10.1016/S0028-3908(97)00011-7

7 January 2021

Identifiers

DOI

1 reference

4 November 2017

1 reference

PubMed ID

9175618